Bushu Pharma’s continued investments and efforts provide its customers with cutting-edge capabilities, increased capacity and innovative solutions, providing leading pharmaceutical manufacturing and supply chain management services.
SAN ANTONIO, December 15, 2024 /PRNewswire/ — Frost and Sullivan has researched the contract development and manufacturing organization industry and, based on his analysis, recognizes Bushu Pharmaceuticals (Pharma) with the APAC Customer Value Leadership Award 2024. The company is a leading contract development and manufacturing organization (CDMO) of pharmaceuticals and medical devices. Renowned for its comprehensive services from development to distribution, the company has established itself as a market leader with a strong track record of delivering safe, high-quality products on time and cost-effectively. It draws on in-depth domain knowledge, extensive experience, and Good Manufacturing Practices (GMP) certifications from leading international regulatory agencies (e.g., the U.S. Food and Drug Administration). [FDA]European Medicines Agency and Pharmaceuticals and Medical Devices Agency), to establish its strong global presence and supply medicines to 56 countries.
Bushu Pharma offers comprehensive services and industry-leading capabilities to support customers throughout the product lifecycle, including development, manufacturing, packaging, quality control, regulatory compliance and supply chain management. ‘supply. The company uses its advanced and extensive manufacturing capabilities, extensive specialized facilities and highly skilled workforce to produce a broad spectrum of pharmaceutical products, ranging from small molecule drugs to complex biologics (including highly potent and sterile). Bushu Pharma excels in managing complex processes, such as product testing and technical transfer (i.e. ensuring consistency, quality and regulatory compliance when transferring analytical methods, validation processes and manufacturing procedures from a customer’s site to its facilities). Its unrivaled capabilities ensure consistent delivery of exceptional quality assurance, on-time delivery and competitive costs, making it a preferred partner in the APAC region. Bushu Pharma continues to invest in the latest technologies, introducing automated guided forklifts and two-armed humanoid collaborative robots to improve efficiency, increase productivity and ensure high safety and quality standards.
Rubini Kamalbest practices research analyst at Frost & Sullivan, observed: “Bushu Pharma’s strategic focus on building partnerships addresses critical challenges related to drug availability and market entry, enhancing its offers while filling market gaps and improving accessibility to healthcare.
Bushu Pharma prioritizes operational excellence and rigorous quality control, thereby establishing itself as a safe and reliable manufacturer in the pharmaceutical sector. Bushu’s Continuity Plan, a resilient and sustainable business system, operates effectively during large-scale disasters and pandemic conditions to ensure continued production and supply of pharmaceutical products to patients around the world. Bushu Pharma’s facilities, equipped with temperature monitoring and safety systems, ensure that pharmaceutical products are optimally stored and handled to maintain their effectiveness and safety. Real-time monitoring also improves security measures, preventing unauthorized access and protecting sensitive documents. Bushu Pharma improves customer value through strong environmental sustainability measures, including implementation of LED lighting with motion sensors, installation of solar panels, transition to renewable energy, quality monitoring wastewater and the adoption of paper bins and biomass films for packaging in its factories. Bushu Pharma’s continued commitment to retaining customer trust and creating value is evident in its global customer base of over 95 commercial clients, of which 50% them from affiliated clients abroad. Its unwavering commitment to improving services, technologies and expertise enables Bushu Pharma to lead the CDMO sector into its next phase of growth, capture market share and maintain its leadership in the years to come. come.
“Bushu Pharma’s innovative GATEWAY towards ASIA services streamline market entry for international customers, while strategic partnerships facilitate efficient product distribution and address regional challenges. The company significantly reduces Asian market entry times, maintains reduced inventory levels and reduces logistics costs and carbon emissions for global pharmaceutical companies compared to traditional supply chains,” Kamal added. This commitment consolidates its reputation as a trusted and reliable partner. With its strong overall performance, Bushu Pharma wins Frost & Sullivan’s APAC Customer Value Leadership Award 2024 in the Contract Development and Manufacturing Organization sector.
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving return on investment that customers make in its services or products. This award recognizes the company’s unique focus on increasing the value its customers receive, beyond just quality customer service, thereby leading to improved customer retention and expansion.
The Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service and strategic product development. Industry analysts compare market players and measure performance through in-depth interviews, analysis, and extensive secondary research to identify industry best practices.
About Frost & Sullivan
For six decades, Frost & Sullivan has been globally known for helping investors, business leaders and governments navigate economic change and identify disruptive technologies, megatrends, new business models and companies to take action. which results in a continuous flow of growth. opportunities to drive future success. Contact us: start the discussion. Contact us: start the discussion.
Contact:
Tarini Singh
E : Tarini.Singh@frost.com
SOURCE Gros & Sullivan
